Australian biotech company Microbio has been awarded an Australian Government Advanced Manufacturing Growth Centre (AMGC) co-investment of $407,000 to enable the company to establish sovereign manufacturing capabilities in Australia for a test to identify potential biological threats.

The company will manufacture specific oligonucleotides, a unique component used in its product suite, which includes InfectID-BSI, InfectID-COVID and InfectID-SSBA: its patented one-tube, seven-pathogen test to rapidly detect Security Sensitive Biological Agents (SSBAs). 

Read more in the Media Release

Microbio has moved into new laboratories at Brisbane’s Translational Research Institute (TRI) with the aim of eventually setting up domestic manufacturing capability.

More information can be found in the media release.

211019_Microbio_moves_toward_sovereign_manufacturing_of_diagnostic_tests

Contact us

Complete this form to request more information on purchasing InfectID, including the COVID-19 Replicating assay, new product developments, or other enquiries.
  • This field is for validation purposes and should be left unchanged.